Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma, Version 3.2022 Featured Updates to the NCCN Guidelines

William G. Wierda; Jennifer Brown; Jeremy S. Abramson; Farrukh Awan; Syed F. Bilgrami; Greg Bociek; Danielle Brander; Asher A. Chanan-Khan; Steve E. Coutre; Randall S. Davis; Herbert Eradat; Christopher D. Fletcher; Sameh Gaballa; Armin Ghobadi; Muhammad Saad Hamid; Francisco Hernandez-Ilizaliturri; Brian Hill; Paul Kaesberg; Manali Kamdar; Lawrence D. Kaplan; Nadia Khan; Thomas J. Kipps; Shuo Ma; Anthony Mato; Claudio Mosse; Stephen Schuster; Tanya Siddiqi; Deborah M. Stephens; Chaitra Ujjani; Nina Wagner-Johnston; Jennifer A. Woyach; J. Christine Ye; Mary A. Dwyer; Hema Sundar

doi:10.6004/jnccn.2022.0031

Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma, Version 3.2022 Featured Updates to the NCCN Guidelines

William G. Wierda, Jennifer Brown, Jeremy S. Abramson, Farrukh Awan, Syed F. Bilgrami, Greg Bociek, Danielle Brander, Asher A. Chanan-Khan, Steve E. Coutre, Randall S. Davis, Herbert Eradat, Christopher D. Fletcher, Sameh Gaballa, Armin Ghobadi, Muhammad Saad Hamid, Francisco Hernandez-Ilizaliturri, Brian Hill, Paul Kaesberg, Manali Kamdar, Lawrence D. KaplanNadia Khan, Thomas J. Kipps, Shuo Ma, Anthony Mato, Claudio Mosse, Stephen Schuster, Tanya Siddiqi, Deborah M. Stephens, Chaitra Ujjani, Nina Wagner-Johnston, Jennifer A. Woyach, J. Christine Ye, Mary A. Dwyer, Hema Sundar

School of Medicine

Research output: Contribution to journal › Article › peer-review

Abstract

The treatment landscape of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) has significantly evolved in recent years. Targeted therapy with Bruton’s tyrosine kinase (BTK) inhibitors and BCL-2 inhibitors has emerged as an effective chemotherapy-free option for patients with previously untreated or relapsed/refractory CLL/SLL. Undetectable minimal residual disease after the end of treatment is emerging as an important predictor of progression-free and overall survival for patients treated with fixed-duration BCL-2 inhibitor-based treatment. These NCCN Guidelines Insights discuss the updates to the NCCN Guidelines for CLL/ SLL specific to the use of chemotherapy-free treatment options for patients with treatment-naïve and relapsed/refractory disease.

Original language	English (US)
Pages (from-to)	622-634
Number of pages	13
Journal	JNCCN Journal of the National Comprehensive Cancer Network
Volume	20
Issue number	6
DOIs	https://doi.org/10.6004/jnccn.2022.0031
State	Published - Jun 2022

ASJC Scopus subject areas

Oncology

Access to Document

10.6004/jnccn.2022.0031

Cite this

Wierda, W. G., Brown, J., Abramson, J. S., Awan, F., Bilgrami, S. F., Bociek, G., Brander, D., Chanan-Khan, A. A., Coutre, S. E., Davis, R. S., Eradat, H., Fletcher, C. D., Gaballa, S., Ghobadi, A., Saad Hamid, M., Hernandez-Ilizaliturri, F., Hill, B., Kaesberg, P., Kamdar, M., ... Sundar, H. (2022). Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma, Version 3.2022 Featured Updates to the NCCN Guidelines. JNCCN Journal of the National Comprehensive Cancer Network, 20(6), 622-634. https://doi.org/10.6004/jnccn.2022.0031

Wierda, WG, Brown, J, Abramson, JS, Awan, F, Bilgrami, SF, Bociek, G, Brander, D, Chanan-Khan, AA, Coutre, SE, Davis, RS, Eradat, H, Fletcher, CD, Gaballa, S, Ghobadi, A, Saad Hamid, M, Hernandez-Ilizaliturri, F, Hill, B, Kaesberg, P, Kamdar, M, Kaplan, LD, Khan, N, Kipps, TJ, Ma, S, Mato, A, Mosse, C, Schuster, S, Siddiqi, T, Stephens, DM, Ujjani, C, Wagner-Johnston, N, Woyach, JA, Ye, JC, Dwyer, MA & Sundar, H 2022, 'Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma, Version 3.2022 Featured Updates to the NCCN Guidelines', JNCCN Journal of the National Comprehensive Cancer Network, vol. 20, no. 6, pp. 622-634. https://doi.org/10.6004/jnccn.2022.0031

@article{36aa0360fdc44896870f6d8f003f882e,

title = "Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma, Version 3.2022 Featured Updates to the NCCN Guidelines",

abstract = "The treatment landscape of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) has significantly evolved in recent years. Targeted therapy with Bruton{\textquoteright}s tyrosine kinase (BTK) inhibitors and BCL-2 inhibitors has emerged as an effective chemotherapy-free option for patients with previously untreated or relapsed/refractory CLL/SLL. Undetectable minimal residual disease after the end of treatment is emerging as an important predictor of progression-free and overall survival for patients treated with fixed-duration BCL-2 inhibitor-based treatment. These NCCN Guidelines Insights discuss the updates to the NCCN Guidelines for CLL/ SLL specific to the use of chemotherapy-free treatment options for patients with treatment-na{\"i}ve and relapsed/refractory disease.",

author = "Wierda, {William G.} and Jennifer Brown and Abramson, {Jeremy S.} and Farrukh Awan and Bilgrami, {Syed F.} and Greg Bociek and Danielle Brander and Chanan-Khan, {Asher A.} and Coutre, {Steve E.} and Davis, {Randall S.} and Herbert Eradat and Fletcher, {Christopher D.} and Sameh Gaballa and Armin Ghobadi and {Saad Hamid}, Muhammad and Francisco Hernandez-Ilizaliturri and Brian Hill and Paul Kaesberg and Manali Kamdar and Kaplan, {Lawrence D.} and Nadia Khan and Kipps, {Thomas J.} and Shuo Ma and Anthony Mato and Claudio Mosse and Stephen Schuster and Tanya Siddiqi and Stephens, {Deborah M.} and Chaitra Ujjani and Nina Wagner-Johnston and Woyach, {Jennifer A.} and Ye, {J. Christine} and Dwyer, {Mary A.} and Hema Sundar",

year = "2022",

month = jun,

doi = "10.6004/jnccn.2022.0031",

language = "English (US)",

volume = "20",

pages = "622--634",

journal = "JNCCN Journal of the National Comprehensive Cancer Network",

issn = "1540-1405",

publisher = "Cold Spring Publishing LLC",

number = "6",

}

TY - JOUR

T1 - Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma, Version 3.2022 Featured Updates to the NCCN Guidelines

AU - Wierda, William G.

AU - Brown, Jennifer

AU - Abramson, Jeremy S.

AU - Awan, Farrukh

AU - Bilgrami, Syed F.

AU - Bociek, Greg

AU - Brander, Danielle

AU - Chanan-Khan, Asher A.

AU - Coutre, Steve E.

AU - Davis, Randall S.

AU - Eradat, Herbert

AU - Fletcher, Christopher D.

AU - Gaballa, Sameh

AU - Ghobadi, Armin

AU - Saad Hamid, Muhammad

AU - Hernandez-Ilizaliturri, Francisco

AU - Hill, Brian

AU - Kaesberg, Paul

AU - Kamdar, Manali

AU - Kaplan, Lawrence D.

AU - Khan, Nadia

AU - Kipps, Thomas J.

AU - Ma, Shuo

AU - Mato, Anthony

AU - Mosse, Claudio

AU - Schuster, Stephen

AU - Siddiqi, Tanya

AU - Stephens, Deborah M.

AU - Ujjani, Chaitra

AU - Wagner-Johnston, Nina

AU - Woyach, Jennifer A.

AU - Ye, J. Christine

AU - Dwyer, Mary A.

AU - Sundar, Hema

PY - 2022/6

Y1 - 2022/6

N2 - The treatment landscape of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) has significantly evolved in recent years. Targeted therapy with Bruton’s tyrosine kinase (BTK) inhibitors and BCL-2 inhibitors has emerged as an effective chemotherapy-free option for patients with previously untreated or relapsed/refractory CLL/SLL. Undetectable minimal residual disease after the end of treatment is emerging as an important predictor of progression-free and overall survival for patients treated with fixed-duration BCL-2 inhibitor-based treatment. These NCCN Guidelines Insights discuss the updates to the NCCN Guidelines for CLL/ SLL specific to the use of chemotherapy-free treatment options for patients with treatment-naïve and relapsed/refractory disease.

AB - The treatment landscape of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) has significantly evolved in recent years. Targeted therapy with Bruton’s tyrosine kinase (BTK) inhibitors and BCL-2 inhibitors has emerged as an effective chemotherapy-free option for patients with previously untreated or relapsed/refractory CLL/SLL. Undetectable minimal residual disease after the end of treatment is emerging as an important predictor of progression-free and overall survival for patients treated with fixed-duration BCL-2 inhibitor-based treatment. These NCCN Guidelines Insights discuss the updates to the NCCN Guidelines for CLL/ SLL specific to the use of chemotherapy-free treatment options for patients with treatment-naïve and relapsed/refractory disease.

UR - http://www.scopus.com/inward/record.url?scp=85132455187&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85132455187&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2022.0031

DO - 10.6004/jnccn.2022.0031

M3 - Article

C2 - 35714675

AN - SCOPUS:85132455187

SN - 1540-1405

VL - 20

SP - 622

EP - 634

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

IS - 6

ER -

Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma, Version 3.2022 Featured Updates to the NCCN Guidelines

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this